EP0641202A1 - Verwendung von indolonderivaten zur behandlung von gedaechtnisstoerungen, sexuele fehlwirkungen und morbus parkinson - Google Patents
Verwendung von indolonderivaten zur behandlung von gedaechtnisstoerungen, sexuele fehlwirkungen und morbus parkinsonInfo
- Publication number
- EP0641202A1 EP0641202A1 EP93912699A EP93912699A EP0641202A1 EP 0641202 A1 EP0641202 A1 EP 0641202A1 EP 93912699 A EP93912699 A EP 93912699A EP 93912699 A EP93912699 A EP 93912699A EP 0641202 A1 EP0641202 A1 EP 0641202A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- memory disorders
- parkinson
- disease
- sexual dysfunction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to the use of selective dopamine D3 receptor agonists in therapy, for example in the treatment of memory disorders.
- the present invention resides in the identification of such a utility and, in a first aspect, provides selective dopamine D3 receptor agonists for use in therapy.
- the present invention relates to selective dopamine D3 receptor agonists for use in the treatment or prophylaxis of diseases in which agonism of the D3 receptors will prove advantageous, for example, in the treatment of memory disorders, sexual dysfunction and Parkinson's disease.
- Particular selective dopamine D3 receptor agonists include, for example, compounds of the structure (I) :
- each group R is the same or different and is hydrogen or
- R 1 and R ⁇ are the same or different and are each hydrogen or C ⁇ _4alkyl; and n is 1 to 3, or a pharmaceutically acceptable salt thereof.
- the compound ropinirole and other compounds of structure (I) are known in the art, for example as having utility in the treatment of Parkinson's disease (EP 0299602-A) .
- the compounds of structure (I) and, in particular, ropinirole can be prepared according to the procedures described in EP 113964-B.
- Selective dopamine D3 receptor agonists are of use in therapy, in particular in the treatment of memory disorders, for example, in the treatment of impaired cerebral functionality, as well as dementia, amnesia and decreased cognitive capacity; in the treatment of sexual dysfunction in both males and females, in particular in the treatment of male and female impotence; and in the treatment of Parkinson's disease.
- the compounds of structure (I) are formulated into a standard pharmaceutical composition, for example as described in EP 113964-B and EP 0299602-A.
- each dosage unit for oral administration contains preferably from 1 to 50 mg (and for parenteral administration contains preferably from 0.1 to 15 mg) of a compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
- the daily dosage regimen for an adult patient may be, for example, an oral dose of between 1 mg and 100 mg, preferably between 1 mg and 50 mg, or an intravenous, subcutaneous, or
- -y intramuscular dose of between 0.1 mg and 50 mg, preferably 5 between 0.1 mg and 15 mg, of the compound of the formula (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
- the compounds will be administered for a period of continuous therapy.
- the membrane pellet was resuspended in ice-cold 50 mM Tris salts (pH 7.4 @ 37°C) , using an Ultra-Turrax, and recentrifuged at 18,000 - A - r.p.m for 15 in at 4°C in a Sorvall RC5C.
- the membranes were washed two more times with ice-cold 50 mM Tris salts (pH 7.4 ⁇ a 37°C) .
- the final pellet was resuspended in 50 mM Tris salts (pH 7.4 @ 37°C) , and the protein content determined using bovine serum albumin as a standard (Bradford, M. M. (1976) Anal. Biochem. 72, 248-254) .
- the binding data revealed the existence of two binding sites in both human D 2 and D3 receptors.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9210594 | 1992-05-18 | ||
GB929210595A GB9210595D0 (en) | 1992-05-18 | 1992-05-18 | Medical use |
GB929210576A GB9210576D0 (en) | 1992-05-18 | 1992-05-18 | Medical use |
GB9210595 | 1992-05-18 | ||
GB929210594A GB9210594D0 (en) | 1992-05-18 | 1992-05-18 | Medical use |
GB9210576 | 1992-05-18 | ||
PCT/EP1993/001099 WO1993023035A2 (en) | 1992-05-18 | 1993-05-04 | Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0641202A1 true EP0641202A1 (de) | 1995-03-08 |
Family
ID=27266192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93912699A Withdrawn EP0641202A1 (de) | 1992-05-18 | 1993-05-04 | Verwendung von indolonderivaten zur behandlung von gedaechtnisstoerungen, sexuele fehlwirkungen und morbus parkinson |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0641202A1 (de) |
JP (1) | JPH07506823A (de) |
AU (1) | AU4312593A (de) |
WO (1) | WO1993023035A2 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6395744B1 (en) | 1994-04-22 | 2002-05-28 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
FR2742149B1 (fr) * | 1995-12-11 | 1998-02-13 | Inst Nat Sante Rech Med | Nouveaux derives de 2-naphtamides et leurs applications therapeutiques |
PT923551E (pt) * | 1996-08-27 | 2002-09-30 | American Home Prod | Derivados de 4-aminoetoxi indolona |
US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
AR014847A1 (es) * | 1998-04-13 | 2001-03-28 | American Home Prod | 4-amino-(etilamino)-oxindoles agonistas del autoreceptor de dopamina y una composicion farmaceutica que los comprende |
WO1999066909A2 (en) * | 1998-06-22 | 1999-12-29 | Univ Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
CA2251255A1 (en) * | 1998-10-20 | 2000-04-20 | Mcgill University | The use of dopaminergic agents in the management of sexual dysfunction |
AR030557A1 (es) | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
DE10041479A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
MXPA06013759A (es) * | 2004-05-26 | 2007-02-08 | Pfizer | Derivados de indazol e indolona y su uso como productos farmaceuticos. |
EP2603215A4 (de) | 2010-08-11 | 2015-08-05 | Philadelphia Health & Educatio | Neue d3-dopamin-rezeptoragonisten zur behandlung von dyskinesien bei morbus parkinson |
CN105848655B (zh) | 2013-10-28 | 2019-11-08 | 德雷克塞尔大学 | 用于注意力和认知障碍的、以及用于与神经变性障碍相关联的痴呆的新疗法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452808A (en) * | 1982-12-07 | 1984-06-05 | Smithkline Beckman Corporation | 4-Aminoalkyl-2(3H)-indolones |
GB8712073D0 (en) * | 1987-05-21 | 1987-06-24 | Smith Kline French Lab | Medicament |
FR2663638B2 (fr) * | 1990-04-06 | 1995-02-10 | Institut Nal Sante Recherc Medic | Polypeptides ayant une activite de recepteur dopaminergique, acides nucleiques codant pour ces polypeptides et utilisation de ces polypeptides pour le criblage de substances actives sur ces polypeptides. |
GB9015095D0 (en) * | 1990-07-09 | 1990-08-29 | Smith Kline French Lab | Therapeutic method |
-
1993
- 1993-05-04 AU AU43125/93A patent/AU4312593A/en not_active Abandoned
- 1993-05-04 JP JP5519830A patent/JPH07506823A/ja active Pending
- 1993-05-04 WO PCT/EP1993/001099 patent/WO1993023035A2/en not_active Application Discontinuation
- 1993-05-04 EP EP93912699A patent/EP0641202A1/de not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9323035A2 * |
Also Published As
Publication number | Publication date |
---|---|
JPH07506823A (ja) | 1995-07-27 |
AU4312593A (en) | 1993-12-13 |
WO1993023035A3 (en) | 1994-03-03 |
WO1993023035A2 (en) | 1993-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9486455B2 (en) | Compounds for modulating TRPV3 function | |
WO1993023035A2 (en) | Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease | |
TWI401254B (zh) | 用於調節trpv3功能之化合物 | |
US9181219B2 (en) | Compounds of modulating TRPV3 function | |
JP4264850B2 (ja) | 疼痛の処置のためのエピナスチンの使用 | |
TWI404538B (zh) | 砷化合物用於治療疼痛及發炎之用途 | |
US8916550B2 (en) | Compounds for modulating TRPV3 function | |
TW498076B (en) | Modified amino acids and pharmaceutical compositions containing these compounds | |
WO1999064011A1 (fr) | Medicaments | |
JPH06502168A (ja) | アンギオテンシン2アンタゴニスト | |
CN108042542A (zh) | 用于治疗病症的方法和组合物 | |
CA1263654A (en) | Zwitterionic bicyclic compounds and their salts, solvates, hydrates and esters | |
EP0185420A1 (de) | Pharmazeutische Zusammensetzungen von Dihydrocodeine/Ibuprofen und Verfahren | |
EP1206264A2 (de) | Zusammensetzungen und verfahren zur behandlung von opiatintoleranz | |
JPS6391391A (ja) | 2−または3−アリール置換イミダゾ[1,2−a]ビリジン | |
US20220096482A1 (en) | Combination therapies | |
JP3808921B2 (ja) | 細胞接着阻害剤 | |
Walia et al. | Montelukast in pediatric asthma management | |
WO2024016996A1 (zh) | 磷酸萘酚喹在制备治疗自身免疫性疾病药物中的应用 | |
WO1991007178A1 (en) | Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders | |
US20100280061A1 (en) | Novel analgesic that binds filamin a | |
SK8572003A3 (en) | Histamine receptor antagonists | |
IE63194B1 (en) | Antiemesis ergoline derivatives | |
JP3180381B2 (ja) | 抗アルドステロン作用剤 | |
JPH1160483A (ja) | Tnf産生阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19941122 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 19960119 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19960530 |